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SUMMARY 
Background: Fluoroquinolones are key second-line anti-tuberculosis drugs usually used in the treatment of patients 
with Multi-Drug Resistant Tuberculosis (MDR-TB). Anti-TB fluoroquinolones include ciprofloxacin, moxifloxacin, 
gatifloxacin (Gat), ofloxacin and levofloxacin. Resistance to one fluoroquinolone usually translates to resistance to 
the others in the group. 
Objective: To determine whether there is fluoroquinolone resistance in Mycobacterium tuberculosis strains isolated in 
Kenya. 
Design: A retrospective descriptive study involving archived strains from previous studies carried out at the Centre 
for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI) between 2002 and 2007. 
Setting: CRDR, KEMRI. 
Methods: A total of 216 first-line Drug Susceptibility Testing (DST) pre-tested MTB strains were used including 78 
resistant to one or more drugs, and randomly selected 138 susceptible to all four drugs. Of the 78 resistant strains, 
25 were MDR-TB. The strains were subjected to drug susceptibility testing to Gat among other second-line drugs. 
Results: Of the 216 strains tested, 32 [32/216 (14.8%)] showed resistance to second-line drugs. Of these seven [7/32 
(21.9%)] were fully resistant to Gat of which six [6/7 (85.7%)] were mono-resistant strains and one [1/7 (14.3%)] 
with combined resistance strain to Ethionamide. Four [4/25 (16%)] MDR-TB strains showed mono-resistance to 
Gat. 
Conclusion: Presence of Gat resistance especially in MDR-TB patients may significantly contribute to Extensively 
Drug Resistance TB, a more difficult to treat strain than MDR-TB. Therefore strict drug adherence among MDR-
TB patients and proper and appropriate use of flouroquinolones should be implemented in Kenya. 
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Fluoroquinolones have become indispensable in the 
treatment of Multi-Drug Resistant Tuberculosis (MDR-
TB)1. As measured by their in vitro activity against 
Mycobacterium tuberculosis (MTB), the most potent of 
the currently available fluoroquinolones are, in 
descending order, moxifloxacin (MXF), gatifloxacin 
(Gat), levofloxacin (Lev), ofloxacin (Ofl), and 
ciprofloxacin (CIP)2. The first three of these drugs are 
commonly known as anti-pneumococcal 
fluoroquinolones used in community-acquired 
pneumonia. MTB clinical isolates that demonstrate high-
level phenotypic resistance to fluoroquinolones, which 
appears to be predominantly due to gyrA mutations, 
exhibit cross-resistance to all six important 
fluoroquinolones. Unfortunately, resistance to one 
fluoroquinolones usually means resistance to the others3. 
Fluoroquinolones act by inhibiting bacterial DNA gyrase. 
They are less effective than other first-line agents in 
treating TB and are mainly used for patients with MDR-
TB. These are the most promising anti-TB drugs as they 
have the potential to shorten treatment to four months or 
less. This class includes: Gat, MXF, which have an anti-
TB activity four times more potent than other 
fluoroquinolones. Older and cheaper fluoroquoinolones 
which are also used in the treatment of MDR-TB include 
Lev, Ofl and CIP4.  
Patients diagnosed with MDR-TB based on first-line 
Drug Susceptibility Testing (DST) results receive a 
standardised second-line regimen consisting of Gat, Cyc, 
ethionamide and amikacin. Ethambutol and pyrazinamide 
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are also added to the regimen based on first-line DST 
results 5, 6. In Kenya flouroquinolones are used in the 
treatment of MDR-TB patients according to WHO 
standards and are also used in the treatment of other 
bacterial infections. Treatment of MDR-TB takes 18 to 
24 months and must be done on the basis of susceptibility 
testing, it is impossible to treat such patients without this 
information. If treating a patient with suspected MDR-
TB, the patient should be started on streptomycin, 
isoniazid, rifampicin, ethambutol, pyrazinamide, MXF 
and Cyc pending the result of laboratory sensitivity 
testing7. The current WHO recommendations for the drug 
management of patients suspected to have MDR-TB is 
the empiric MDR-TB  regimen6. 
Fluoroquinolones have been widely promoted and used 
for the management of community acquired respiratory 
infections in Kenya including pneumonia. A proportion 
(not less than 10%) of patients with community acquired 
pneumonia, have TB and the use of fluoroquinolones in 
these patients may not only delay the diagnosis of TB but 
also stimulate the development of fluoroqunilones 
resistance in MTB. This study was done to check 
whether there is fluoroquinolone resistance in MTB 
strains isolated in Kenya. 
 
Materials and Methods 
Samples: A total of 216 pre-tested first-line MTB strains 
were used in this cumulative data design study. The 
strains were obtained from previous studies at CRDR, 
KEMRI. They included all first-line drug resistant and 
randomly selected first-line susceptible strains obtained 
between 2002 and 2007. The studies from which these 
strains were obtained had included a Quality Assurance 
(QA) using supranational reference laboratory in 
accordance to the WHO guidelines on DST procedures8. 
Table 1: Spectrum of first-line strains used in the 
study.  




Isoniazid related resistant 
strains (73)  
Rifampicin related resistant 
strains (25)  
Streptomycin related 
resistant strains (24)  
Ethambutol related resistant 
strains (11)  
Multi-drug resistant strains 
(25)  
             138  
 
Laboratory procedures: Subcultures were first done on 
Lowenstein Jensen (LJ) to obtain fresh strains. Drug 
susceptibility testing (DST) was performed on LJ media 
using proportion method. The drug that was used was 
Gat8. 
Drug containing LJ slopes were made by adding 
appropriate amounts of drugs aseptically to LJ media 
before inspissation. First a stock solution was prepared 
and the drug solution sterilised using a membrane filter 
with a size of 0.45µm so as to make the solutions aseptic. 
Suitable working concentrations of the drug were made 
using sterile distilled water and then added aseptically to 
the LJ media. Standard volume of the media was then 
dispensed into sterile universal bottles and then 
inspissated for 45 minutes to 1 hour at a temperature of 
85°C (6).  The final drug concentration used was 0.5 
µg/ml critical concentration8. 
Each bacterial suspension was prepared by adding 
approximately 4 mg moist weight of the test sample of 
the bacterial mass visualized as 2/3 loopful of a 3mm 
internal diameter, 24 standard wire gauge wire loop into 
1 ml of sterile distilled water in a 7 ml Bijou bottle 
containing three 3mm glass beads. This suspension was 
vortexed for 30 seconds to produce a uniform suspension 
of 1.0 McFarland turbidity standard (107 CFU/ml). A 
standardized inoculum of 0.1 ml of the bacterial 
suspension was inoculated onto drug-free and drug 
containing LJ slopes using a loopful of a 3 mm diameter, 
27 standard wire gauge wire loop. These cultures were 
incubated at a temperature of 37°C for four weeks and 
then interpreted8. 
Interpretation of results: The results were interpreted as 
either fully resistant or susceptible according to standard 
methods each isolate was taken and the number of 
colonies resistant to each drug concentration was 
expressed as a percentage of the number of colonies 
growing on the drug-free slope. The critical proportion 
regarded as 1%8. 
Quality control: All manipulations were done in a class 
II biosafety conditions. Control strain MTB H37Rv and 
known resistance strains were included in each new batch 
of media. LJ media was prepared using fresh eggs (less 
than seven days old) and sterility check was carried out 
on all batches of media by incubating a few slopes of the 
LJ media randomly at 37°C for at least five days and 
checked daily to ensure that there was no contamination. 
All batches of media for DST were stored at 4°C for not 
longer than four weeks from date of preparation. 
Preparation of suspensions from each strain was done 
using individual sterile wire loops per strain to avoid 
cross-contamination between the strains9. 
Ethical considerations: This study was approved by both 
the Kenya Medical Research Institute (KEMRI) 
Scientific Steering Committee (SSC) and the National 
Ethical Review Committee (ERC). 
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Data analysis: Using S.P.S.S. computer data analysis 
programme, data was analysed using chi-square to 
compare resistance and susceptibility among the drugs 
and to compare resistance and susceptibility between the 
first-line susceptible and resistant strains10. The data was 
presented in form of tables. 
 
Results 
Of the 216 strains tested, 32 [32/216 (14.8%)] showed 
resistance to second-line drugs. Of these 7 [7/32 (21.9%)] 
were fully resistant to Gat. Of the 25 MDR-TB strains, 4 
(16%) were fully resistant to Gat and 21 (84%) were 
sensitive to it (Table 2). Of the 7 strains, 6 (41.2%) were 
mono-resistant to Gat and one combined resistance with 
ethionamide. 
Of the 25 rifampicin resistant strains tested, 21 (84%) 
were found to be sensitive and 4 (6%) were fully resistant 
to Gat. Of the 73 isoniazid resistant strains, 67 (91.8%) 
were sensitive and 6 (8.2%) were fully resistant to Eth. 
Of the 11 ethambutol resistant strains, 9 (81.8%) were 
sensitive and 2 (18.2%) fully resistant to Eth. Of the 24 
streptomycin resistant strains, 22 (91.7%) were sensitive 
and 2 (8.3%) were fully resistant to Eth (Table 3). 
 
Table 2: Susceptibility profile of gatifloxacin 
 Sensitive n (%) 




Susceptibility profile of the 216 MTB strains 
to Gat. 209 (96.76) 7 (3.24) 216 (100) 
Susceptibility profile of the 138 first-line 
sensitive MTB isolates to Gat 137 (99.27) 1 (0.72) 138 (100) 
Susceptibility profile of the 78 first-line 
resistant MTB isolates to Gat 72 (92.3) 6 (7.69) 78 (100) 
Susceptibility profile of the 25 MDR–TB 
strains 21 (84) 4 (16) 25 (100) 
 








Rifampicin (25) 21 (84) 4 (6) 0.004 (*) 
Isoniazid (73) 67 (91.8) 6 (8.2) 0.007 (NS) 
Ethambutol (11) 9 (81.8) 2 (18.2) 0.016 (NS) 
Streptomycin (24) 22 (91.7) 2 (8.3) 0.176 (NS) 
 
*- statistically significant, NS-not statistically significant. 
 
Discussion 
Fluoroquinolones have broad-spectrum antimicrobial 
activity and so are widely used for the treatment of 
bacterial infections of the respiratory, gastrointestinal and 
urinary tracts, as well as sexually transmitted diseases 
and chronic osteomyelitis11, 12. They have been 
demonstrated to be active in vitro and in vivo against 
mycobacteria species and effective in the treatment of 
infections caused by MTB, M. leprae and atypical 
mycobacteria such as M. fortuitum13. They exhibit very 
good bactericidal activity against mycobacteria and act 
by binding to complexes of bacterial DNA and DNA 
gyrases, thereby interfering with DNA replication14. 
This study on MTB fluoroquinolone resistance is the first 
of its kind in Kenya. Resistance was found in MTB 
strains isolated in Kenya. This resistance may jeopardize 
the potential for these drugs as a second-line anti-TB 
agents in the programmatic management of drug-resistant 
TB and creating incurable TB strains. Researchers have 
identified an MTB protein that confers fluoroquinolone 
resistance via a novel mechanism14. 
Fluoroquinolone resistance in MTB can develop after as 
little as 13 days of fluoroquinolone therapy22. Kenya’s 
pharmaceutical industry is highly liberalized and there is 
hardly any pharmcovigilance for quality of drugs 
circulating in the Kenyan market. The presence of 
fluoroquinolone counterfeit drugs or drugs of inferior or 
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unknown quality could also stimulate the development of 
drug resistance even if those drugs are used rationally. 
Fluoroquinolone resistance occurred in both MDR-TB 
and Non-MDR-TB strains in this study. MDR-TB strains 
showing in vitro resistance to fluoroquinolones be a pre-
requisite for extensively drug-resistant (XDR-TB) strains 
which is defined as MDR-TB strain that is resistant to an 
injectable second-line aminoglycoside (e.g. kanamycin) 
and one fluoroquinolone. It has been documented before 
that fluoroquinolone resistance in MTB seems to develop 
very rapidly15. 
This study showed one strain that was susceptible to all 
first-line drugs but was resistant to Gat. In Kenya 
fluoroquinolones are mainly used in the treatment of 
urinary tract infections, gonorrhea and drug-resistant TB. 
Patients with prior exposure to any of the 
fluoroquinolones are likely to develop resistance to other 
fluoroquinolones. Being broad spectrum antibacterial 
agents, their widespread and indiscriminate use, often in 
sub-therapeutic doses, is likely to rapidly enhance 
fluoroquinolone-resistant organisms, including 
mycobacteria16. Widespread use of these antibiotics for 
the treatment of other bacterial infections may select for 
fluoroquinolone-resistant MTB strains17, but the extent to 
which this use can have an impact on the selection of 
fluoroquinolone- resistant mutants of MTB is not 
known18. Recent studies showed that previous 
fluoroquinolone use and MDR-TB were associated with 
its resistance in MTB strains19, 20. There is also possible 
danger of development of fluoroquinolone resistance if a 
patient co-infected with MTB is treated with a 
fluoroquinolone for another infection, pharmacovigilance 
is required17. 
In a study done be Peng Xu et al, fluoroquinolone 
resistance was independently associated with resistance 
to at least one first-line drug and prior TB treatment21. In 
this study, resistance to Gat was also statistically 
associated with first-line anti-TB resistance. 
  
Conclusions 
Presence of Gat resistance especially in MDR-TB 
patients may trigger XDR-TB. Therefore strict drug 
adherence among MDR-TB should be implemented. 
Overuse and inappropriate use of fluoroquinolones may 
also lead to the loss of these drugs as effective 
medications against MDR-TB or other diseases. 
Fluoroquinolones resistance was correlated with first-line 
drug resistance statistically, suggesting the need for 
routine fluoroquinolones susceptibility testing in patients 





Presence of fluoroquinolone-resistant TB in Kenya may 
call for DST to second-line drugs for MDR-TB patients 
before start of therapy since fluroquinolones are key 
drugs. There should also be restriction on the use of 
fluoroquinolones so as to preserve them for future use in 
MDR-TB treatment.  
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